Aptazapine (CGS-7525A) was a tetracyclic antidepressant developed in the 1980s. Aptazapine had noradrenergic and specific serotonergic activity. It antagonised ?2 adrenergic receptors approximately 10 times more effectively than mianserin, antagonised 5-HT2 receptors, agonised H1 receptors, and did not affect reuptake of serotonin or norepinephrine. Although Aptazapine reached clinical trials, it was never marketed.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Tranylcypromine | The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Aptazapine. |
| Phenelzine | The risk or severity of adverse effects can be increased when Phenelzine is combined with Aptazapine. |
| Selegiline | The risk or severity of adverse effects can be increased when Selegiline is combined with Aptazapine. |
| Moclobemide | The risk or severity of adverse effects can be increased when Moclobemide is combined with Aptazapine. |
| Isocarboxazid | The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Aptazapine. |
| Rasagiline | The risk or severity of adverse effects can be increased when Rasagiline is combined with Aptazapine. |
| Pargyline | The risk or severity of adverse effects can be increased when Pargyline is combined with Aptazapine. |
| Minaprine | The risk or severity of adverse effects can be increased when Minaprine is combined with Aptazapine. |
| Iproniazid | The risk or severity of adverse effects can be increased when Iproniazid is combined with Aptazapine. |
| Nialamide | The risk or severity of adverse effects can be increased when Nialamide is combined with Aptazapine. |
| Pirlindole | The risk or severity of adverse effects can be increased when Pirlindole is combined with Aptazapine. |
| Toloxatone | The risk or severity of adverse effects can be increased when Toloxatone is combined with Aptazapine. |
| Hydracarbazine | The risk or severity of adverse effects can be increased when Hydracarbazine is combined with Aptazapine. |
| Methylene blue | The risk or severity of adverse effects can be increased when Methylene blue is combined with Aptazapine. |
| Benmoxin | The risk or severity of adverse effects can be increased when Benmoxin is combined with Aptazapine. |
| Mebanazine | The risk or severity of adverse effects can be increased when Mebanazine is combined with Aptazapine. |
| Octamoxin | The risk or severity of adverse effects can be increased when Octamoxin is combined with Aptazapine. |
| Pheniprazine | The risk or severity of adverse effects can be increased when Pheniprazine is combined with Aptazapine. |
| Phenoxypropazine | The risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Aptazapine. |
| Pivhydrazine | The risk or severity of adverse effects can be increased when Pivhydrazine is combined with Aptazapine. |
| Safrazine | The risk or severity of adverse effects can be increased when Safrazine is combined with Aptazapine. |
| Caroxazone | The risk or severity of adverse effects can be increased when Caroxazone is combined with Aptazapine. |
| Furazolidone | The risk or severity of adverse effects can be increased when Furazolidone is combined with Aptazapine. |
| 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline | The risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Aptazapine. |
| Harmaline | The risk or severity of adverse effects can be increased when Harmaline is combined with Aptazapine. |
| Brofaromine | The risk or severity of adverse effects can be increased when Brofaromine is combined with Aptazapine. |
| Procaine | The risk or severity of adverse effects can be increased when Procaine is combined with Aptazapine. |
| Procarbazine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Aptazapine. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Aptazapine. |
| Safinamide | The risk or severity of adverse effects can be increased when Safinamide is combined with Aptazapine. |
| Clorgiline | The risk or severity of adverse effects can be increased when Clorgiline is combined with Aptazapine. |
| Levothyroxine | The risk or severity of adverse effects can be increased when Levothyroxine is combined with Aptazapine. |